Document:

Exhibit 10.34

 

STOCK PURCHASE AGREEMENT

 

This Stock Purchase Agreement (“Agreement”)
is made and entered into this 12th day of June, 2020, by and between ElectroMedical Technologies, Inc., a Delaware
corporation, with a business address of 16561 N 92nd Street Ste. 101, Scottsdale AZ 85260 (“Seller”), and ProActive
Capital Partners, LP, a Delaware limited partnership, with a business address of 150 E. 58th St. 20th Floor, New York, NY 10155
(“Purchaser”). Both Seller and Purchaser are referred to individually as a “Party” and jointly
as the “Parties.”

 

RECITALS

 

WHEREAS, Seller is
a clinical stage a bioelectronics manufacturing and marketing company selling medical devices for pain management. Its Wellness
Pro product received FDA clearance on July 6, 2007 (FDA K062616) as a Class II Medical Device, under the 510(K) clearance
process.

 

WHEREAS,
Seller filed Regulation “A” offering on September 20, 2017 on Form 1-A. Seller has filed all required
Regulation “A” reports to maintain its offering to date. Seller filed a Form S-1 registration statement on
November 12, 2019, as amended. All of Seller’s disclosures filed with the Securities and Exchange Commission
(“SEC”) are available on Seller’s SEC Edgar web
site (https://www.sec.gov/cgi-bin/browse-edgar?company=Electromedical&owner=exclude&action=getcompany).
The SEC has not made the Form S-1 effective as of the date hereof. As of the date of this Agreement, Seller is not
subject to the periodic reporting requirements of the 1934 Securities and Exchange Act and the regulations implementing the
Exchange Act SEC. Seller’s common stock is quoted on the OTC Markets, Inc. Pink tier electronic listing service
trading under the symbol “ELCQ”; and,

 

WHEREAS, Seller desires
to sell and Purchaser desires to purchase one hundred and forty two thousand, eight hundred and fifty-seven (142,857) restricted
shares of Seller’s common stock (“Purchased Shares”) at a price of thirty five cents ($0.35) per share
on the terms and subject to the conditions set forth in this Agreement.

 

AGREEMENT

 

NOW, THEREFORE, in consideration of the
mutual covenants and agreements contained in this Agreement, the sufficiency and adequacy of which are acknowledged by the Parties,
and in order to consummate the purchase and the sale of the Purchased Shares, it is hereby agreed as follows:

 

1. Purchase and Sale. Subject
to the terms and conditions hereinafter set forth, at the Closing (defined below), Seller shall sell, convey, transfer, and deliver
to Purchaser a certificate or book entry confirmation of the issuance representing the Purchased Shares, in consideration of the
Purchase Price. The certificates representing the Purchased Shares shall be duly issued in the name of the Purchaser. The Purchaser’s
address is 150 E. 58th Street 20th Floor, New York, NY 10155. The Purchaser’s tax identification number is 82-3535071.

 

    1

     

    

 

2. Amount of Purchase Price.
As total consideration for the purchase of the Purchased Shares, Purchaser shall pay to Seller at the Closing the purchase price
(“Purchase Price”) of fifty thousand dollars ($50,000.00). Seller’s wire transfer instructions are: Electromedical
Technologies, Bank of America, Routing number: 122101706, Account number: 457023402995.

 

3. Representations and Warranties of Seller. Seller
hereby warrants and represents:

 

(a) Seller has all requisite power
and authority to execute, deliver, and perform its obligations under this Agreement, and, when executed and delivered by Seller,
shall constitute the valid and binding obligation of Seller, enforceable against Seller in accordance with its terms, subject to
applicable bankruptcy, insolvency, reorganization, fraudulent conveyance, moratorium or other similar laws affecting creditors’
rights and remedies generally, and subject, as to enforceability, to general principles of equity (regardless of whether enforcement
is sought in a proceeding at law or in equity);

 

(b) The Purchased Shares have been
duly authorized and, when conveyed by Seller to Purchaser at the Closing, all in accordance with the terms of this Agreement, will
be duly and validly issued, fully paid and non-assessable;

 

(c) Neither the execution or delivery
of this Agreement, nor any other documents required to be executed and delivered by Seller hereunder, nor the consummation of the
transaction contemplated hereby: (i) conflicts with or constitutes any violation or breach, or gives any other person any
rights (including, but not limited to, any legal rights to acceleration, termination, cancellation or recession) under any document
or agreement to which Seller is a party. Neither Seller’s entry into this Agreement, nor Seller’s representations made
in this Agreement, constitute a violation of any order or applicable law that Seller or to which Seller’s assets are bound
by or subject; and

 

(d) Seller is a corporation validly
existing and in good standing under the laws of the State of Delaware.

 

4. Representations and Warranties
of Purchaser. Purchaser hereby warrants and represents:

 

(a) Purchaser has all requisite corporate
power and authority to execute, deliver and perform its obligations under the Agreement, and the execution, delivery, and performance
by Purchaser of its obligations under the Agreement has been duly authorized by all requisite action on the part of Purchaser and
the Agreement, when executed and delivered by Purchaser, shall constitute the valid and binding obligation of Purchaser, enforceable
against Purchaser in accordance with its terms, subject to applicable bankruptcy, insolvency, reorganization, fraudulent conveyance,
moratorium or other similar laws affecting creditors’ rights and remedies generally, and subject, as to enforceability, to
general principles of equity (regardless of whether enforcement is sought in a proceeding at law or in equity);

 

    2

     

    

 

(b) With respect to the Purchased
Shares acquired by Purchaser, Purchaser acknowledges that the Purchased Shares have not been registered under the Securities Act
of 1933, as amended (“Securities Act”) and are “Restricted Securities” within the meaning
of Rule 144 under the Securities Act. As such, the Purchased Shares may not be resold or transferred unless Seller registers
them in an SEC effective registration under Section 5 of the Securities Act, or has received an opinion of counsel to Seller
or any successor in interest thereto reasonably satisfactory to Seller that such resale or transfer is exempt from the registration
requirements of the Securities Act. Purchaser acknowledges that a no public market exists for the Purchased Shares. Purchaser understands
that no assurance can be given that such a trading market will further develop at any time, or, if so developed, that it will continue;

 

(c) Purchaser further
acknowledges and agrees that its purchase of the Purchased Shares involves substantial risks. Purchaser: (i) either
alone or together with its representatives has such knowledge and experience in financial and business matters as to be
capable of evaluating the merits and risks of this investment, and make an informed decision to so invest, and has so
evaluated the risks and merits of such investment; (ii) has the ability to bear the economic risks of this investment
for an indefinite period and can afford a complete loss of such investment; (iii) understands the terms of, and the
risks associated with the acquisition of the Purchased Shares, including, without limitation, a lack of liquidity, price
transparency or pricing availability and risks associated with the industry in which Seller operates; (iv) has had the
opportunity to review such disclosures regarding Sellers’s business, financial condition and prospects
as Purchaser has determined to be necessary in connection with the acquisition of the Purchased Shares, including
Seller’s public filings with the SEC, and the risk factors set forth therein, (v) is an “accredited
investor" as that term is defined in Regulation D promulgated under Securities Act; (vi) acknowledges and
agrees that the Purchased Shares are being offered and sold to it in reliance on specific exemptions from the registration
requirements of United States federal and state securities laws and that the Seller is relying upon the truth and accuracy
of, and such Purchaser’s compliance with, the representations, warranties, agreements, acknowledgments and
understandings of such Purchaser set forth herein in order to determine the availability of such exemptions and the
eligibility of such Purchaser to acquire the Purchased Shares; and (viii) understands and acknowledges that no United
States federal or state agency or any other government or governmental agency has passed on or made any recommendation or
endorsement of the Securities or the fairness or suitability of the investment in the Securities nor have such authorities
passed upon or endorsed the merits of the offering of the Securities.

 

(d) Purchaser has received or
has had full access to all the information Purchaser considers necessary or appropriate to make an informed investment
decision with respect to the Purchased Shares. Purchaser further has had an opportunity to ask questions of and receive
answers from the management of Seller regarding the Purchased Shares and to obtain additional information necessary to verify
any information furnished to Purchaser or to which Purchaser had access. Further, Purchaser has undertaken its own review of
the business of Seller and the wisdom of an investment in the Purchased Shares. Purchaser has had the opportunity to review
all of the books, records and all SEC filings of Seller, including all of Seller’s audited financial statements and
disclosures that Seller has published concerning its operations as a company reporting to the SEC;

 

    3

     

    

 

(e) Purchaser is acquiring the Purchased
Shares for its own account, and not with a view towards a public distribution of those Purchased Shares as an underwriter for Seller,
as that term is defined in the Securities Act. Purchaser acknowledges that it is not acquiring the Purchased Shares as the result
of any advertisement or solicitation, including any publicly issued or circulated newspaper, mail, radio, television or other form
of general advertising or solicitation in connection with the offer, sale and purchase from Seller regarding Purchaser’s
investment pursuant to this Agreement; and

 

(f) Purchaser represents that Purchaser
is familiar with the requirements of Rule 144 of the Securities Act, as presently in effect, and understands the resale limitations
imposed thereby. Purchaser understands that Seller is under no obligation to register any of the Purchased Shares. Purchaser acknowledges
that the certificates or book entry registry for the Purchased Shares, will be noted as “Restricted” on the transfer
agent’s ledger, or, if a certificate it issued, it will bear a legend substantially in the form set forth below:

 

THE SECURITIES REPRESENTED HEREBY HAVE
NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (“ACT”), OR UNDER THE SECURITIES LAWS OF ANY OTHER
JURISDICTION. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD
EXCEPT AS PERMITTED UNDER THE ACT AND THE APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM. PURCHASERS
SHOULD BE AWARE THAT THEY MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME.

 

(g) Purchaser is a corporation validly
existing and in good standing under the laws of the State of Delaware.

 

5. Representations, Warranties and Covenants of Seller
and Purchaser.

 

(a) Seller and Purchaser hereby represent
and warrant that there has been no act or omission by Seller or Purchaser which would give rise to any valid claim against any
of the Parties for a brokerage commission, finder's fee or other like payment in connection with the transaction contemplated hereby,
except for such claims as shall have been waived on or before the Closing Date;

 

(b) The representations and
warranties of Seller and Purchaser contained herein or in any document furnished pursuant hereto shall survive the Closing of
this transaction. Each Party acknowledges and agrees that, except as expressly set forth in this Agreement or any closing
document, no Party has made (and no Party is relying on) any representation or warranties of any nature, express or implied,
regarding anything relating to the transaction contemplated by this Agreement that are not contained herein; and

 

    4

     

    

 

(c) Purchaser and Seller agree that
each will, at any time and from time to time after the Closing, upon the request of the other Party, do, execute, acknowledge and
deliver, or will cause to be done, executed, acknowledged and delivered, all such further acts, assignments, transfers, conveyances,
powers of attorney and assurances as may be reasonably required from time to time in order to effectuate the provisions and purposes
of this Agreement.

 

6. Conditions to Purchaser’s
Obligations at Closing.

 

(a) Representations and Warranties.
Each of the representations and warranties of Seller shall be true and complete on and as of the Closing; and

 

(b) Performance. Seller shall
have performed and complied with all agreements, obligations and conditions contained in this Agreement that are required to be
performed or complied with by him on or before the Closing.

 

7. Conditions to Seller’s Obligations
at Closing.

 

(a) Representations and Warranties.
Each of the representations and warranties of Purchaser shall be true and complete on and as of the Closing; and

 

(b) Payment of Purchase Price.
Purchaser shall have delivered to Seller the Purchase Price for the Purchased Shares to be acquired by Purchaser pursuant to this
Agreement.

 

8. The Closing. Subject to
the satisfaction or waiver of the conditions in this Agreement, the closing of the sale to the Purchaser (“Closing”)
shall take place on or before June 12, 2020 (or on such other date as is mutually agreed upon by the Parties) (“Closing
Date”). On the Closing Date, Purchaser shall pay the Purchase Price to Seller by wire transfer of immediately available
funds to Seller’s account at Bank of America, with wire instructions provided in Section 2 above. Seller’s wire
transfer instructions are: Electromedical Technologies, Bank of America, Routing number: 122101706, Account number: 457023402995.

 

9. General Provisions.

 

(a) Entire Agreement. This
Agreement constitutes the entire agreement between the parties and supersedes all prior agreements and understandings, oral and
written, between the Parties with respect to the subject matter hereof. This Agreement may not be amended except by a written agreement
signed by Purchaser and Seller.

 

(b) Sections and Other
Headings; Interpretation. The section and other headings contained in this Agreement are for reference purposes only and
shall not affect the meaning or interpretation of this Agreement. Whenever the context requires, words used in the singular
shall be construed to mean or include the plural and vice versa, and pronouns of any gender shall be deemed to include and
designate the masculine, feminine or neuter gender.

 

    5

     

    

 

(c) Governing Law; Jurisdiction.
This Agreement shall be deemed to be a contract made under the laws of the State of New York. This Agreement and the construction,
validity, enforcement, performance and interpretation of, or any dispute or claim arising out of or in relation to, this Agreement
(whether in contract, tort or otherwise) shall be construed in accordance with the laws of the State of New York without giving
effect to the rules of the State of New York governing the conflicts of laws (other than Section 5-1401 of the General
Obligations Law of the State of New York). Each Party agrees that all legal proceedings concerning the interpretations, enforcement
and defense of this Agreement and the transactions herein contemplated (“Proceedings”) (whether brought against
a Party or its respective Affiliates, employees or agents) shall be commenced exclusively in the New York Courts. Each Party hereto
hereby irrevocably submits to the exclusive jurisdiction of the New York Courts for the adjudication of any dispute hereunder or
in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees
not to assert in any Proceeding, any claim that it is not personally subject to the jurisdiction of any New York Court, or that
such Proceeding has been commenced in an improper or inconvenient forum. Each Party hereby irrevocably waives personal service
of process and consents to process being served in any such Proceeding by mailing a copy thereof via registered or certified mail
or overnight delivery (with evidence of delivery) to such Party at the address in effect for notices to it under this Agreement
and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein
shall be deemed to limit in any way any right to serve process in any manner permitted by law. Each Party hereby irrevocably, knowingly
and voluntarily waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any Proceeding
arising out of or relating to this Agreement or the transactions contemplated hereby. For purposes of this Agreement, “New
York Courts” means the state and federal courts sitting in the State of New York, City of New York, Borough of Manhattan.

 

(d) Severability. If any provision
of this Agreement is determined by any court of competent jurisdiction to be invalid, illegal or unenforceable in any respect,
such provision will be enforced to the maximum extent possible given the intent of the Parties hereto. If such clause or provision
cannot be so enforced, such provision shall be stricken from this Agreement and the remainder of this Agreement shall be enforced
as if such invalid, illegal or unenforceable clause or provision had (to the extent not enforceable) never been contained in this
Agreement.

 

(e) Counterparts. This
Agreement may be executed in one or more counterparts, each of which will be deemed to be an original copy of this Agreement
and all of which, when taken together, will be deemed to constitute one and the same agreement. In the event that any
signature is delivered by facsimile transmission or by e-mail delivery of a “.pdf” format data file, such
signature shall create a valid and binding obligation of the Party executing (or on whose behalf such signature is executed)
with the same force and effect as if such facsimile or “.pdf” signature page were an original thereof.

 

    6

     

    

 

(f) Waiver. The rights and
remedies of the Parties are cumulative and not alternative. Neither the failure nor any delay by any Party in exercising any right,
power, or privilege under this Agreement, or the documents referred to in this Agreement, will operate as a waiver of such right,
power, or privilege, and no single or partial exercise of any such right, power, or privilege will preclude any other or further
exercise of such right, power, or privilege or the exercise of any other right, power, or privilege.

 

(g) Successors and Assigns.
Except as otherwise provided in this Agreement, this Agreement, and the rights and obligations of the Parties hereunder, will be
binding upon and inure to the benefit of the Parties’ respective successors, assigns, heirs, executors, administrators and
legal representatives.

 

(h) Survival of Warranties.
The representations, warranties and covenants of Seller and Purchaser contained in or made pursuant to this Agreement shall survive
the execution and delivery of this Agreement and the Closing.

 

(i) Notices. All notices, requests
and demands (“Notice”) to or upon a Party, to be effective, shall be in writing and shall be sent: (i) certified
or registered mail, return receipt requested; (ii) by personal delivery against receipt; (iii) by overnight courier;
or (iv) by email and, unless otherwise expressly provided herein, and shall be deemed to have been validly served, given,
delivered and received: (x) on the date indicated on the receipt, when delivered by personal delivery against receipt or by
certified or registered mail; (y) one business day after deposit with an overnight courier; or (z) in the case of email
notice, when sent. Notices shall be addressed as follows:

 

To Seller:

 

ElectroMedical Technologies, Inc. 

Attention: Matthew Wolfson, CEO 

16561 N 92nd Street Ste. 101 

Scottsdale AZ 85260 

Email: ceo@electromedtech.com

 

With a copy to: 

Mailander Law Office, Inc. 

4811 49th Street 

San Diego, CA 92101 

tmailander@gmail.com

 

To Purchaser:

 

ProActive Capital
Partners, LP

150 E. 58th
Street 20th Floor

New York, NY
10155

 

    7

     

    

 

Either Party may change the address to
which Notices shall be addressed by providing Notice of such change to the other Party in the manner set forth in this subsection
9(i).

 

(j) Third Parties. Nothing
in this Agreement, express or implied, is intended to confer upon any person, other than the Parties hereto and their successors
and assigns, any rights or remedies under or by reason of this Agreement.

 

(k) Preparation of Agreement.
Seller prepared this Agreement solely on its behalf. Each Party to this Agreement acknowledges that: (i) the Party had the
advice of, or sufficient opportunity to obtain the advice of, legal counsel separate and independent of legal counsel for any other
Party hereto; (ii) the terms of the transactions contemplated by this Agreement are fair and reasonable to such Party; and
(iii) such Party has voluntarily entered into the transactions contemplated by this Agreement without duress or coercion.
Each Party further acknowledges that such Party was not represented by the legal counsel of the other Party in connection with
the transactions contemplated by this Agreement, nor was he or it under any belief or understanding that such legal counsel was
representing his or its interests. Each Party agrees that no conflict, omission or ambiguity in this Agreement, or the interpretation
thereof, shall be presumed, implied, or otherwise construed against the other Party on the basis that such Party was responsible
for drafting this Agreement.

 

IN WITNESS WHEREOF, each of the undersigned has duly executed
this Stock Purchase Agreement as of the date first written above.

 

	SELLER	 
	 	 
	ElectroMedical
    Technologies, Inc.	 
	a
    Delaware corporation	 
	 	 
	By:  	  	 
	 	Printed
    Name: Matthew Wolfson	 
	 	Title:
    Chief Executive Officer	 

 

PURCHASER

 

ProActive Capital
Partners, LP 

a Delware Limited
Partnership

 

	By:  	  	 
	 	Printed Name: Jeff Ramson	 
	 	Title: Authorized Signatory	 

 

    8Exhibit 10.35

 

 

SECURITIES PURCHASE AGREEMENT

 

This SECURITIES
PURCHASE AGREEMENT (this “Agreement”), dated as of June 4, 2020, is entered into by and between ELECTROMEDICAL
TECHNOLOGIES, INC., a Delaware corporation,
(the “Company”), and VISTA CAPITAL INVESTMENTS,
LLC (the “Buyer”).

 

A.            The
Company and the Buyer are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded
by the rules and regulations as promulgated by the United States Securities and Exchange Commission (the “SEC”)
under the Securities Act of 1933, as amended (the “1933 Act”).

 

B.            Upon
the terms and conditions stated in this Agreement, the Buyer desires to purchase and the Company desires to issue and sell, upon
the terms and conditions set forth in this Agreement (i)  a Promissory Note of the Company, in the form attached hereto as
Exhibit  A, in the original principal amount of $110,000.00 (together with any note(s)  issued in replacement
thereof or as a dividend thereon or otherwise with respect thereto in accordance with the terms thereof, the “Note”),
(ii)  one hundred thousand (100,000) restricted common shares in the Company (“Commitment Shares”) to be
delivered to Holder, via overnight courier , within 5 busine ss days following the Closing Date, and (iii) a three -year share
purchas e warrant entitling the Buyer to acquire 250,000 com mon shares (“Common Stock” ), in the form attached
her eto as Exhibit B (the “Warrant”) (together, the “Securities”).

 

NOW
THEREFORE, the Company and the Buyer hereby agree as follows:

 

1.            Purchase
and Sale. On the Closing Date (as defined below), the Company shall issue and sell to the Buyer and the Buyer agrees to purchase
from the Company (i) the Note in the original principal amount of $110,000, and (ii) the Commitment Shares.

 

1.1.            Form of
Payment. On the Closing Date, (i) the Buyer shall pay the purchase price of $100,000 (the “Purchase Price”)
for the Securities to be issued and sold to it at the Closing (as defined below) by wire transfer of immediately available funds
to a company account designated by the Company, in accordance with the Company’s written wiring instructions, against delivery
of the Securities, and (ii) the Company shall deliver such duly executed Securities on behalf of the Company, to the Buyer,
against delivery of such Purchase Price.

 

1.2.            Closing
Date. The date and time of the issuance and sale of the Securities pursuant to this Agreement (the “Closing Date”)
shall be on or about June 4, 2020, or such other mutually agreed upon time. The closing of the transactions contemplated by
this Agreement (the “Closing”) shall occur on the Closing Date at such location as may be agreed to by the parties.

 

1.3.            Commitment
Share True-Up. If, during the period beginning on the Closing Date and ending on the later of (i) the Maturity Date,
or (ii) the date on which the Note is fully satisfied and cancelled (the “True-Up Period”), the then the
greater of (i) $0.25 and (ii) the lowest traded price (as reported by Quotestream TM, a service of
Quotemedia, Inc.) of the Company’s common stock (the “Common Stock”) for any Trading Day within the
True-Up Period (the “Subsequent Share Price”), as reported on the Company’s Principal Market, is less than
the closing price of the Company’s common stock on the Issuance Date, then the Company shall, within three
(3) trading days of Holder’s provision of written notice in the form attached hereto as Exhibit C (the
 “True-Up Notice”), issue and deliver to the Holder an additional number of duly and validly issued, fully paid
and non-assessable shares of Common Stock equal to (X) the quotient of the Commitment Value (as defined below) divided
by the Subsequent Share Price, multiplied by 1.5, less (Y) the Commitment Shares, less (Z) any True-Up Shares (as
defined below) previously issued. The “Commitment Value” shall mean the product of the Commitment Shares
multiplied by the closing price of the Company’s common stock on the Closing Date. Any additional shares of Common
Stock issuable pursuant to Section 1.d are referred to herein as “True-up Shares.” The Holder shall not
submit more than one True-Up Notice. The True-up Shares, if required to be issued pursuant to this Note, shall be issued as
provided in this Note, provided, however, that in no event shall the Holder be entitled to receive shares of common stock in
excess of the amount that would result in beneficial ownership by the Holder and its affiliates of 9.99% of the outstanding
shares of Common Stock at that time. For purposes of the proviso to the immediately preceding sentence, beneficial ownership
shall be determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended (the
 “Exchange Act”), and Regulations 13D-G thereunder. Accordingly, the True-up Shares, if required to be issued
pursuant to this Note, shall be issued in accordance with the beneficial ownership limitations contained herein, and in
successive tranches (each an “Additional Tranche”) if the issuance of one tranche would result in the
Holder’s beneficial ownership of more than 9.99% of the outstanding shares of Common Stock at that time. The Company
shall issue each respective Additional Tranche of the True-up Shares, if required under this Note, within two
(2) Trading Days of the request by Holder, subject to the beneficial ownership limitations contained herein. If the
Company fails to issue the True-up Shares or any Additional Tranche within the timeframe specified in this Note, then the
amount of Additional Shares in which Holder is entitled shall automatically be multiplied by two. The Company shall at all
times reserve shares of its Common Stock for Holder in an amount equal to 300% multiplied by (X) the quotient of the
Commitment Value divided by the lowest traded price of the Common Stock during the five Trading Days immediately preceding
the respective date of calculation, multiplied by 1.5, less (Y) the Original Shares.

 

     

     

    

 

1.4.            Registration
Rights: The Company shall, within ten (10) calendar days of the effectiveness of the S-1 Registration statement initially
filed with the SEC on November 12, 2019, file a registration statement form S-1MEF with the SEC to register 500,000 (five
hundred thousand) shares in the name of the Buyer. Failure to do so will result in an Event of Default under the Note.

 

2.            Governing
Law; Miscellaneous.

 

2.1.            Governing
Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Nevada without regard to
principles of conflicts of laws. Any action brought by either party against the other concerning the transactions contemplated
by this Agreement shall be brought only in the state courts of San Diego County, California or in the federal courts located in
San Diego County, California. The parties to this Agreement hereby irrevocably waive any objection to jurisdiction and venue of
any action instituted hereunder and shall not assert any defense based on lack of jurisdiction or venue or based upon forum
non conveniens. In the event that any provision of this Agreement or any other agreement delivered in connection herewith is
invalid or unenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperative to the
extent that it may conflict therewith and shall be deemed modified to conform with such statute or rule of law. Any such provision
which may prove invalid or unenforceable under any law shall not affect the validity or enforceability of any other provision of
any agreement. Each party hereby irrevocably waives personal service of process and consents to process being served in any suit,
action or proceeding in connection with this Agreement or any other Transaction Document by mailing a copy thereof via registered
or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under
this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing
contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. THE COMPANY
HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE
HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.

 

    2 

     

    

 

2.2.            Counterparts.
This Agreement may be executed in one or more counterparts, each of which shall be deemed an original but all of which shall
constitute one and the same agreement and shall become effective when counterparts have been signed by each party and
delivered to the other party.

 

2.3.            Headings.
The headings of this Agreement are for convenience of reference only and shall not form part of, or affect the interpretation of,
this Agreement.

 

2.4.            Severability.
In the event that any provision of this Agreement is invalid or unenforceable under any applicable statute or rule of law,
then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform
with such statute or rule of law. Any provision hereof which may prove invalid or unenforceable under any law shall not affect
the validity or enforceability of any other provision hereof.

 

2.5.            Entire
Agreement; Amendments. This Agreement and the instruments referenced herein contain the entire understanding of the parties
with respect to the matters covered herein and therein and, except as specifically set forth herein or therein, neither the Company
nor the Buyer makes any representation, warranty, covenant or undertaking with respect to such matters. No provision of this Agreement
may be waived or amended other than by an instrument in writing signed by the Buyer.

 

2.6.            Notices.
Any notice required or permitted hereunder shall be given in writing (unless otherwise specified herein) and shall be deemed effectively
given on the earliest of:

 

(a)            the
date delivered, if delivered by personal delivery as against written receipt therefor or by e-mail to an executive officer, or
by confirmed facsimile,

 

(b)            the
fifth Trading Day after deposit, postage prepaid, in the United States Postal Service by registered or certified mail, or

 

(c)            the
third Trading Day after mailing by domestic or international express courier, with delivery costs and fees prepaid, in each case,
addressed to each of the other parties thereunto entitled at the following addresses (or at such other addresses as such party
may designate by ten (10) calendar days’ advance written notice similarly given to each of the other parties hereto):

 

    3 

     

    

 

If to
the Company, to:

 

Electromedical
Technologies, Inc.

16561
N 92nd St., Suite 101

Scottsdale
AZ 85260

Attn:
Matthew Wolfson

Email:
ceo@electromedtech.com

 

If to
the Buyer:

 

VISTA CAPITAL INVESTMENTS, LLC

120 Birmingham Drive, Suite 230

Cardiff CA 92007

Attn: David Clark

Email: dclark@vci.us.com

 

2.7.            Successors
and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and assigns.
Notwithstanding anything to the contrary herein, the rights, interests or obligations of the Company hereunder may not be assigned,
by operation of law or otherwise, in whole or in part, by the Company without the prior written consent of the Buyer, which consent
may be withheld at the sole discretion of the Buyer; provided, however, that in the case of a merger, sale of substantially
all of the Company’s assets or other corporate reorganization, the Buyer shall not unreasonably withhold, condition or delay
such consent. This Agreement or any of the severable rights and obligations inuring to the benefit of or to be performed by Buyer
hereunder may be assigned by Buyer to a third party, including its financing sources, in whole or in part, without the need to
obtain the Company’s consent thereto.

 

2.8.            Third
Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective permitted successors
and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other person.

 

2.9.            Survival.
The representations and warranties of the Company and the agreements and covenants set forth in this Agreement shall survive the
Closing hereunder notwithstanding any due diligence investigation conducted by or on behalf of the Buyer. The Company agrees to
indemnify and hold harmless the Buyer and all its officers, directors, employees, attorneys, and agents for loss or damage arising
as a result of or related to any breach or alleged breach by the Company of any of its representations, warranties and covenants
set forth in this Agreement or any of its covenants and obligations under this Agreement, including advancement of expenses as
they are incurred.

 

2.10.            No
Strict Construction. The language used in this Agreement will be deemed to be the language chosen by the parties to express
their mutual intent, and no rules of strict construction will be applied against any party.

 

2.11.            Remedies.
The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Buyer by vitiating
the intent and purpose of the transaction contemplated hereby. Accordingly, the Company acknowledges that the remedy at law for
a breach of its obligations under this Agreement will be inadequate and agrees, in the event of a breach or threatened breach by
the Company of the provisions of this Agreement, that the Buyer shall be entitled, in addition to all other available remedies
at law or in equity, and in addition to the penalties assessable herein, to an injunction or injunctions restraining, preventing
or curing any breach of this Agreement and to enforce specifically the terms and provisions hereof, without the necessity of showing
economic loss and without any bond or other security being required.

 

    4 

     

    

 

2.12.            Buyer’s
Rights and Remedies Cumulative. All rights, remedies, and powers conferred in this Agreement and the Transaction Documents
on the Buyer are cumulative and not exclusive of any other rights or remedies, and shall be in addition to every other right, power,
and remedy that the Buyer may have, whether specifically granted in this Agreement or any other Transaction Document, or existing
at law, in equity, or by statute; and any and all such rights and remedies may be exercised from time to time and as often and
in such order as the Buyer may deem expedient.

 

2.13.            Ownership
Limitation. If at any time after the Closing, the Buyer shall or would receive shares of Common Stock in payment of
interest or principal under Note, upon conversion of Note, under the Warrant, or upon exercise of the Warrant, so that the
Buyer would, together with other shares of Common Stock held by it or its Affiliates, own or beneficially own by virtue of
such action or receipt of additional shares of Common Stock a number of shares exceeding 4.99% of the number of shares of
Common Stock outstanding on such date (the “Maximum Percentage”), the Company shall not be obligated and
shall not issue to the Buyer shares of Common Stock which would exceed the Maximum Percentage, but only until such time as
the Maximum Percentage would no longer be exceeded by any such receipt of shares of Common Stock by the Buyer. The foregoing
limitations are enforceable, unconditional and non-waivable and shall apply to all Affiliates and assigns of the Buyer.
Additionally, for so long as the Buyer or any of its Affiliate own Securities, upon written request from the Buyer, the
Company shall post (or cause to be posted), the then-current number of issued and outstanding shares of its capital stock to
the Company’s web page located at OTCmarkets.com (or such other web page approved by the Buyer).

 

2.14.            Attorneys’
Fees and Cost of Collection. In the event of any action at law or in equity to enforce or interpret the terms of this Agreement
or any of the other Transaction Documents, the parties agree that the party who is awarded the most money shall be deemed the prevailing
party for all purposes and shall therefore be entitled to an additional award of the full amount of the attorneys’ fees and
expenses paid by such prevailing party in connection with the litigation and/or dispute without reduction or apportionment based
upon the individual claims or defenses giving rise to the fees and expenses. Nothing herein shall restrict or impair a court’s
power to award fees and expenses for frivolous or bad faith pleading.

 

[Remainder of page intentionally
left blank; signature page to follow]

 

    5 

     

    

 

SUBSCRIPTION
AMOUNT:

 

	Original Principal Amount of Note: 	$110,000.00
	Purchase Price: 	$100,000.00 

 

IN WITNESS WHEREOF,
the undersigned Buyer and the Company have caused this Agreement to be duly executed as of the date first above written.

 

THE COMPANY:

 

Electromedical
Technologies, Inc.

	 	 	 
	By:		 
	 	Matthew Wolfson	 
	 	Chief Executive Officer	 

 

	THE BUYER:	 
	 	 	 
	VISTA
CAPITAL INVESTMENTS, LLC	 
	 	 	 
	By:		 
	 	David J. Clark	 
	 	Managing Member	 

 

     

     

    

 

EXHIBIT A

 

NOTE

 

     

     

    

 

EXHIBIT B

 

 WARRANT

 

 

     

     

    

 

EXHIBIT C

 

TRUE-UP NOTICE

VISTA CAPITAL INVESTORS, LLC

 

Date:                                                     

 

		[Company]	

 

		[Address]	

 

TRUE-UP NOTICE

 

The above-captioned
Holder hereby gives notice to [Company], a Nevada corporation (the “Company”), pursuant to that certain Securities
Purchase Agreement dated _______ by and between the Company and the Holder (the “Purchase Agreement”), that
the Holder elects to receive fully paid and nonassessable True-Up Shares pursuant to Section 1.3 of the Purchase Agreement.
Such True-Up Shares shall be calculated as set forth below. In the event of a conflict between this True-Up Notice and the Purchase
Agreement, the Purchase Agreement shall govern, or, in the alternative, at the election of the Holder in its sole discretion, the
Holder may provide a new form of True-Up Notice to conform to the Purchase Agreement.

 

		A.	Subsequent Share Price: ______

		B.	Commitment Value: $_______

		C.	Commitment Shares: ______ *

		D.	Commitment Shares ______

	 	E.	Previously Issued True-Up Shares _______

 

The number of True-Up Shares
Holder is entitled to receive is calculated as follows:

 

((Commitment Value / Subsequent
Share Price) x 1.5) – (Commitment Shares) – (Previously Issued True-Up Shares) = True-Up Shares Deliverable

 

* Subject to adjustments permitted
by the Transaction Documents.

 

Please transfer the Additional Origination Shares electronically
(via DWAC) to the following account:

 

	 	 	Broker:	 
	 	 	Address:	 
	 	 	 	 
	 	 	DTC#:	 

 

Account #:

Account Name:

 

	To the extent the Additional Origination Shares are not able to be delivered to the Holder
    electronically via the DWAC system, please deliver a certificate representing all such shares to the Holder via reputable overnight courier after receipt of this True-Up Notice (by facsimile transmission
or otherwise) to:

 

_____________________________________

_____________________________________

_____________________________________

 

	Sincerely,	 
	 	 
	VISTA CAPITAL INVESTMENTS,
    LLC	 
	 	 
	By: 	 	 
	 	David J. Clark, President	 
	 	 

    7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}]]